SSA
CPRX

Sierra Summit Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Sierra Summit Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26,715
Closed -$580K – 188
2025
Q2 		$580K Buy
26,715
+237
+0.9% +$5.59K 0.1% 145
2025
Q1 		$642K Buy
+26,478
New +$596K 0.14% 111

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Sierra Summit Advisors's CPRX Position: Q3 2025 in Review

Sierra Summit Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q3 2025, closing a stake of 26,715 shares — an estimated $580K sold.

Sierra Summit Advisors first reported a position in CPRX in Q1 2025 and held it in 2 quarters. The position peaked at $642K in Q1 2025. 360 funds tracked by Wall St. Rank hold CPRX as of Q3 2025.

  • Sierra Summit Advisors reported no remaining Catalyst Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Sierra Summit Advisors sold 26,715 Catalyst Pharmaceutical shares in Q3 2025, an estimated $580K.
  • Sierra Summit Advisors first reported a position in Catalyst Pharmaceutical in Q1 2025 and held it in 2 quarters.
  • Sierra Summit Advisors's Catalyst Pharmaceutical position peaked at $642K in Q1 2025.
  • 360 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2025.

Based on Sierra Summit Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.